Aerie Pharmaceuticals agrees to acquire Avizorex Pharma

This article was originally published here

AVX completed a Phase 2a study in dry eye subjects earlier this year with its lead product candidate, AVX-012. The active ingredient in AVX-012 is a potent and

The post Aerie Pharmaceuticals agrees to acquire Avizorex Pharma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply